OSLO, Norway, May 16, 2017 /PRNewswire/ --
Press Release no: 14/2017
Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel
targeted therapeutics for haematological cancers, will announce its first quarter 2017 results on Wednesday, 24th of
May 2017.
A presentation by Nordic Nanovector's senior management team will take place at 8:30 am CET
at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: NYLAND
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2017 from
7:00 am CET the same day.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs
and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological
cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC)
designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major
types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector
intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
CONTACT:
For further information, please contact:
IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47-91-51-95-76
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: mark.swallow@citigatedr.co.uk / david.dible@citigatedr.co.uk
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-first-quarter-2017-results-presentation-and-webcast,c2266801
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-first-quarter-2017-results-presentation-and-webcast-300458403.html
SOURCE Nordic Nanovector